title: Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers.
abstract: OBJECTIVE
  To analyze whether the presence of anti-HBs in liver transplant recipients is effective in preventing HBV infection.
  
  
  METHODS
  Twenty-three patients receiving anti-HBc positive liver were studied. Nine recipients were anti-HBc positive as a result of previous HBV infection. Of them, one also received HBV vaccine during the pre-liver transplantation period. Fourteen recipients were anti-HBs positive due to HBV vaccine administered during the pre-transplant period. Liver biopsy was obtained in 10/14 anti-HBc negative/anti-HBs positive recipients and in 4/9 anti-HBc positive recipients.
  
  
  RESULTS
  After a mean follow-up period of 46 months, 1 recipient with protective serum anti-HBs levels developed de novo HBV infection as a consequence of immune escape HBV mutants. Among the 14 vaccinated anti-HBc negative/anti-HBs positive recipients, 1/10 patients with available liver biopsy (10%) had liver HBV-DNA at 13 mo post-liver transplantation without serum viral markers and did not develop de novo HBV infection. The vaccinated anti-HBc positive recipient without HBV vaccine response was HBV-DNA positive in serum and liver, viral DNA was continuously negative in the following tests, so a spontaneous seroconversion was diagnosed.
  
  
  CONCLUSIONS
  The presence of anti-HBs as a result of HBV vaccine or past HBV infection seems to be effective at protecting patients receiving livers from anti-HBc positive donors. However, the emergence of immune escape HBV mutants, which can evade the anti-HBs protection, should be considered as a risk of HBV infection.
authors.affiliation: Department of Gastroenterology, Hospital Ramón y Cajal, Facultad de Medicina, Universidad de Alcalá, Ctra. Colmenar Km 9.1, 28034 Madrid, Spain. rbarcena.hrc@salud.madrid.org
authors.forename: Rafael
authors.initials: R
authors.lastname: Barcena
authors.forename: Gloria
authors.initials: G
authors.lastname: Moraleda
authors.forename: Javier
authors.initials: J
authors.lastname: Moreno
authors.forename: M Dolores
authors.initials: MD
authors.lastname: Martín
authors.forename: Emilio
authors.initials: E
authors.lastname: de Vicente
authors.forename: Jesús
authors.initials: J
authors.lastname: Nuño
authors.forename: M Luisa
authors.initials: ML
authors.lastname: Mateos
authors.forename: Santos
authors.initials: S
authors.lastname: del Campo
mesh_terms: D000328:Adult; D000368:Aged; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D017325:Hepatitis B Vaccines / Q000276:immunology; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D014019:Tissue Donors
chemical_list: D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D017325:Hepatitis B Vaccines